CHANDRA KING: Open Payments
NPI 1710660089 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$667 in 18 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $55 · 2025 $667
Food & beverage: $667
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $356 |
| Novo Nordisk Inc | 4 | $81 |
| Corcept Therapeutics | 3 | $55 |
| ABBVIE INC. | 2 | $52 |
| Astellas Pharma US Inc | 2 | $48 |
| Lilly USA, LLC | 1 | $30 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
Products named: BREZTRI, FARXIGA, Korlym, UBRELVY, Veozah, Ozempic, ZEPBOUND, AIRSUPRA.
Industry payments across ID — which companies pay providers there.
